Despite replacing him with Doctor Doom, Kevin Feige is still "proud" of the Kang performance in Quantumania
In a recent Empire interview, Marvel Studios head Kevin Feige acknowledged that “Ant‑Man and the Wasp: Quantumania” fell short of internal expectations, yet he singled out the portrayal of Kang the Conqueror as a high point. The comment comes after Disney terminated Jonathan Majors’s contract in early 2024 following his December 2023 conviction for reckless assault and harassment. At the time, the fifth Avengers film was slated to be “The Kang Dynasty,” but Feige revealed that the narrative shift toward Doctor Doom was already in motion, independent of Majors’s legal troubles. The revised project, retitled “Avengers: Doomsday,” is set for a December 18, 2024 release and will feature an expanded roster that pulls characters from the former Fox properties—including the X‑Men and Fantastic Four—alongside the Thunderbolts, Thor (Chris Hemsworth), Sam Wilson’s Captain America (Anthony Mackie), and the original Steve Rogers (Chris Evans). By anchoring the sequel around a classic villain rather than a recently introduced antagonist, Marvel hopes to restore audience confidence after the lukewarm reception of its Phase 5 entry.
The pivot reflects a broader industry pattern where studios recalibrate franchise trajectories after a misstep. Marvel’s decision mirrors Disney’s earlier strategy of re‑tooling the “Guardians of the Galaxy” sequels after mixed reactions, and it underscores the high stakes of maintaining momentum in a multi‑billion‑dollar MCU. Moreover, integrating the Fox X‑Men and Fantastic Four signals Disney’s intent to finally monetize its 2019 acquisition, aligning with the competitive push from rival universes—such as Warner Bros.’ DC “Super‑team” films—to assemble sprawling, cross‑property ensembles. The choice of Doctor Doom, a villain with deep comic‑book roots, also suggests Marvel is leaning on nostalgia and iconic antagonists to draw broader demographics, especially after the recent controversy surrounding a lead actor.
Looking ahead, the success of “Avengers: Doomsday” will hinge on whether audiences accept a villain‑driven narrative that bypasses Kang’s unresolved arcs. Watch for how Marvel addresses Majors’s storyline—whether through recasting, retconning, or off‑screen resolution—in the lead‑up media. Additionally, box‑office performance will be a litmus test for the viability of the newly merged Fox characters; a weak debut could force Disney to rethink its integration timeline, while a strong showing would validate the aggressive expansion strategy. Finally, the December release date pits the film against holiday blockbusters, so marketing will need to emphasize the novelty of Doom’s central role to differentiate it from competing spectacles.
Key Takeaways
Feige admits “Quantumania” missed targets but praises Jonathan Majors’s Kang, highlighting a split between commercial results and creative satisfaction.
Marvel’s shift from “The Kang Dynasty” to “Avengers: Doomsday” was already underway before Majors’s legal issues, indicating a strategic pivot rather than a reactive scramble.
The December 2024 release will be the first MCU film to combine the former Fox X‑Men, Fantastic Four, and Thunderbolts with core MCU heroes, testing Disney’s integration of its 2019 acquisition.
Box‑office reception of “Doomsday” will determine whether Marvel continues to prioritize iconic villains like Doctor Doom over newer antagonists such as Kang.
About the Source
This analysis is based on reporting by GamesRadar. Here is a short excerpt for context:
Kevin Feige acknowledges Quantumania underperformed, but he still likes KangRead the original at GamesRadar